Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

NCT04288765 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped incomplete recruitment

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab Only Product in Parenteral Dose Form

Sponsor

Grupo Cooperativo de Hemopatías Malignas